Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

Dividend forecasts raised after balance sheet regains strength.

Esther Holloway | 13 August 2026

Stocks that had been posting triple-digit returns are sliding on earnings results.

Karen Gilchrist | 12 August 2026

Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.

Nathan Zaia | 12 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,381.40	9.10	-0.10%
CAC 40	8,650.56	24.38	-0.28%
DAX 40	26,299.74	31.33	-0.12%
Dow JONES (US)	53,839.99	69.72	0.13%
FTSE 100	10,772.67	60.48	-0.56%
HKSE	25,396.51	43.66	-0.17%
NASDAQ	26,803.03	214.54	0.81%
Nikkei 225	68,308.59	784.53	1.16%
NZX 50 Index	13,825.30	87.64	0.64%
S&P 500	7,798.99	50.49	0.65%
S&P/ASX 200	9,188.50	4.40	-0.05%
SSE Composite Index	3,926.96	19.71	-0.50%